Un anticuerpo optimizado con especificidad para CD19/CD22/CD3 ha mostrado potencial para la inmunoterapia oncológica, en un modelo murino de leucemia linfoblástica aguda de células B. Puede leer un comentario al respecto en Müller D. Optimized CD19/CD22/CD3 antibody. Blood, 2022;140(16):1750–1751.
– Targeting inflammation to improve regulatory T cell therapy for immunopathologies. Proc Natl Acad Sci U S A. 2022;119(44):e2215271119.
– Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med 2022; 387:1264-1278.
– Responsiveness to interleukin-15 therapy is shared between tissue-resident and circulating memory CD8+ T cell subsets. Proc Natl Acad Sci U S A. 2022;119(44):e2209021119.
– Inhibition of FOXP3 by stapled alpha-helical peptides dampens regulatory T cell function. Proc Natl Acad Sci U S A. 2022;119(44):e2209044119.
– HSCT for adults with immunodeficiencies. Blood, 2022;140(14):1580–1581.
En la sección: Inflamación, Inmunodeficiencias, Inmunología clínica, Inmunología en otras especialidades, Inmunoterapia, Linfocitos T. Publicado en: .
– Vázquez-Blomquist D, Bequet-Romero M, Mendoza-Marí Y, Lemos G, Valdés I, Canaán-Haden C, et al. Nasalferon, a new nasal formulation of IFNa2b, modulates cellular and molecular elements associated with an antiviral response in mucosa and blood. Clinical Immunology Communications, 2022;2:39-45.
– González S, Amador Y, Boris LG, Mojena L, Soler LL, Pish G, et al. Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin. J Oncol. 2022 Sep 1;2022:4128946.
En la sección: COVID-19, Infectología, Inmunidad innata, Inmunidad tumoral, Inmunoterapia. Publicado en: .
– Carmenate T, Montalvo G, Lozada SL, Rodriguez Y, Ortiz Y, Díaz C, et al. The antitumor effect induced by an IL-2 ‘no-alpha’ mutein depends on changes in the CD8 + T lymphocyte/Treg cell balance. Front Immunol. 2022 Aug 17;13:974188.
– Evans R, Lee K, Wallace PK, Reid M, Muhitch J, Dozier A, et al. Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC. Front Oncol. 2022 Aug 3;12:958043.
En la sección: Autores cubanos en revistas extranjeras, Inmunidad tumoral, Inmunoterapia, Linfocitos T. Publicado en: .
– A new chapter for anti-idiotypes in low molecular weight compound immunoassays. Trends in Biotechnology, 2022;40(9):1102-1120.
– Chronic Urticaria. N Engl J Med 2022;387:824-831.
– Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations. BMJ 2022;378:e068956.
– Refractory immune thrombocytopenia: lessons from immune dysregulation disorders. Front. Med., 2022; doi: 10.3389/fmed.2022.986260.
– Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review of PubMed/MEDLINE case reports from 1980 to 2020. Front. Med., 2022; https://doi.org/10.3389/fmed.2022.949520
– The roles of extracellular vesicles in the immune system. Nature Reviews Immunology, 2022; https://doi.org/10.1038/s41577-022-00763-8
– The evolving role of tissue-resident memory T cells in infections and cancer. Science Advances, 2022;8(33).
En la sección: Artículos de revisión, Autoinmunidad, Hipersensibilidad, Inmunidad tumoral, Inmunoterapia, Linfocitos T, Tecnologías. Publicado en: .
– Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.
– Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.
– Monoclonal Antibodies — A Different Approach to Combat Malaria.
– Monoclonal Antibodies for Malaria.
– Monoclonal Antibody Therapy in Parkinson’s Disease — The End?
– An anti-CTLA-4 heavy chain–only antibody with enhanced Treg depletion shows excellent preclinical efficacy and safety profile.
– Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial.
– Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab.
En la sección: Autoinmunidad, Infectología, Inmunidad tumoral, Inmunología en otras especialidades, Inmunoterapia, Neuroinmunología. Publicado en: .